Iceland's impressive handling of the COVID-19 pandemic has positioned it as a real-world laboratory for viral research. Its genetically homogeneous population offers unique insights into the coronavirus, drawing on decades of genetic expertise from local leaders like deCODE Genetics.
Among Iceland's 360,000 residents, the COVID-19 record stands out: 1,789 cases and just 10 deaths. Geographic isolation helps, but the country's proactive screening sets it apart. As Bloomberg reported on April 21, 2020, Iceland tested about 10% of its population—surpassing rates in Spain and Germany, while France tested only 0.7%.
Pioneering this effort is deCODE Genetics, a company with over 20 years in population genetics. They provided free tests to anyone, regardless of symptoms. This approach, proportionally the most extensive globally, curbed the outbreak. Notably, researchers found that half of positive cases were asymptomatic.
Beyond testing, Iceland's edge lies in its population. deCODE Genetics analyzed confirmed cases, identifying over 40 virus strains through genotyping to trace origins. Since emerging in Wuhan, COVID-19 has accumulated mutations.
By cross-referencing viral data with patient genetics, researchers probe how genes influence disease progression—whether from host genetics, viral variants, or their interplay. Key questions include why the virus proves severe in some and mild in others.
Iceland's small, genetically homogeneous population—with minimal immigration and traceable family links among nearly all citizens—makes this feasible. deCODE has already sequenced the genomes of one-third of Icelanders and continues this vital work.
